Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas

Journal of Neuro-Oncology

Volumn 107, Issue 3, 2012, Pages 527-535

  Colavolpe, Cécile ^a,b   Metellus, Philippe ^a,c   Mancini, Julien ^a   Barrie, Maryline ^a   Béquet Boucard, Céline ^a   Figarella Branger, Dominique ^a,c   Mundler, Olivier ^a,b   Chinot, Olivier ^a,c   Guedj, Eric ^a,b  

^a TIMONE HOSPITAL   (France)

^b Aix Marseille University   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

FDG PET; High grade gliomas; Prognosis; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; ANAPLASTIC GLIOMA; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; DRUG UPTAKE; EVENT FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HAZARD RATIO; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; BRAIN TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

ADULT; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84864329014     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0771-6     Document Type: Article

References (57)

1. Kleihues P, Cavenee WK (2000) World Health Organization Classification of Tumours.Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323-331
4. Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198
5. Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710
6. Gupta T, Sarin R (2002) Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3:557-564
7. Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38
8. Mittler MA, Walters BC, Stopa EG (1996) Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg 85:1091-1094
9. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393
10. Morita M, Rosenblum MK, Bilsky MH, Fraser RA, Rosenfeld MR (1996) Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 27:259-266
11. Scott JN, Rewcastle NB, Brasher PM et al (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183-188
12. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
13. Bourguet P, Blanc-Vincent MP, Boneu A et al (2003) Summary of the standards, options and recommendations for use of positron emission tomography with 2[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Br J Cancer 89:S84-S91
14. Vander Borght T, Asenbaum S, Bartenstein P et al (2006) EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 33:1374-1380
15. DiChiroG,DeLaPazRL,BrooksRAet al (1982)Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329
16. De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49:157-163
17. Alavi JB, Alavi A, Chawluk J et al (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62:1074-1078
18. Mineura K, Sasajima T, Kowada M et al (1994) Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 73:2386-2394
19. Barker FG II, Chang SM, Valk PE, Pounds TR, Prados MD (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115-126
20. Kim CK, Alavi JB, Alavi A, Reivich M (1991) New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 10:85-91
21. Patronas NJ, Di Chiro G, Kufta C et al (1985) Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62:816-822
22. Padma MV, Said S, Jacobs M et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227-237
23. Kaschten B, Stevenaert A, Sadzot B et al (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778-785
24. Colavolpe C, Guedj E, Metellus P et al (2008) FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. J Neurooncol 90:47-51
25. Spence AM, Muzi M, Graham MM et al (2002) 2-(18F)Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 8:971-979
26. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
27. Hamacher K, Coenen HH, Stöcklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-(18F)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238
28. Schifter T, Hoffman JM, Hanson MW et al (1993) Serial FDGPET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17:509-561
29. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
30. Pardo FS, Aronen HJ, Fitzek M et al (2004) Correlation of FDGPET interpretation with survival in a cohort of glioma patients. Anticancer Res 24:2359-2365
31. Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B (2006) Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 246:85-94
32. Giammarile F, Cinotti LE, Jouvet A et al (2004) High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol 68:263-274
33. Meyer PT, Schreckenberger M, Spetzger U et al (2001) Comparison of visual and ROI-based brain tumour grading using 18FFDG PET: ROC analyses. Eur J Nucl Med 28:165-174
34. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A (1999) Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 26:1501-1509
35. Kim S, Chung JK, Im SH et al (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18FFDG PET. Eur J Nucl Med Mol Imaging 32:52-59
36. Pötzi C, Becherer A, Marosi C et al (2007) (11C) methionine and (18F) fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol 84:305-314
37. Herholz K, Wienhard K, Heiss WD (1990) Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2:240-265
38. Goldman S, Levivier M, Pirotte B et al (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78:1098-1106
39. Macbeth RAL, Bekesi JG (1962) Oxygen consumption and anaerobic glycolysis of human malignant and normal tissue. Cancer Res 22:244-248
40. Yamamoto T, Seino Y, Fukumoto H et al (1990) Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170:223-230
41. Graham JF, Cummins CJ, Smith BH, Kornblith PL (1985) Regulation of hexokinase in cultured gliomas. Neurosurgery 17:537-542
42. Galanaud D, Chinot O, Metellus P, Cozzone P (2005) Magnetic resonance spectroscopy in gliomas. Bull Cancer 92:327-331
43. Hamstra DA, Chenevert TL, Moffat BA et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-toprogression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102:16759-16764
44. De Witte O, Goldberg I, Wikler D et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746-750
45. Nojiri T, Nariai T, Aoyagi M et al (2009) Contributions of biological tumor parameters to the incorporation rate of L[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93:233-241
46. Floeth FW, Pauleit D, Sabel M et al (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519-527
47. Torii K, Tsuyuguchi N, Kawabe J et al (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19:677-683
48. Ribom D, Eriksson A, Hartman M et al (2001) Positron emission tomography (11)C-methionine and survival in patients with lowgrade gliomas. Cancer 92:1541-1549
49. Pöpperl G, Kreth FW, Mehrkens JH et al (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933-1942
50. Talbot JN, Kerrou K, Montravers F, Nataf V, Chevalme Y (2007) FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Eur J Nucl Med Mol Imaging 34:1131-1132
51. Heiss WD, Wienhard K, Wagner R et al (1996) F-dopa as an amino acid tracer to detect brain tumors. J Nucl Med 37:1180-1182
52. Chen W, Silverman DH, Delaloye S et al (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904-911
53. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18FFDG. J Nucl Med 46:945-952
54. Cher LM, Murone C, Lawrentschuk N et al (2006) Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47:410-418
55. Schnell O, Krebs B, Carlsen J et al (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 11:861-870
56. Spence AM, Muzi M, Mankoff DA et al (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45:1653-1659
57. Di Chiro G (1987) Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22:360-371